Gross Annual Premium

In insurance, the gross annual premium refers to the total amount of premium paid by the policyholder for coverage over a one-year period before any deductions or credits are applied. It includes the base premium as well as any additional charges, such as fees for optional riders or increased coverage limits.

For example, if a policyholder purchases a home insurance policy with a base premium of $1,000 per year, and also adds a $100 rider for coverage of high-value jewelry, the gross annual premium would be $1,100.

Key features of gross annual premium:

• It represents the total cost of the insurance policy for a one-year period.

• It includes both the base premium and any additional charges, such as fees for optional coverage or riders.

• The gross annual premium is typically paid in one lump sum at the start of the coverage period.

• Deductions or credits may be applied to the gross annual premium, such as discounts for multiple policies or claims-free history.

• The amount of the gross annual premium is determined by various factors, such as the insured's age, location, claims history, and the level of coverage selected.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.